| Protocol Title |
Study # |
Study Group |
| A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (NAB-PACLITAXEL) (NSC-736631) With or Without Bevacizumab, Either Preceded By or Followed By Q 2 Week Doxorubicin (A) and Cyclophosphamide Plus Pegfilgrastim (PEG-G) as Neoadjuvant Therapy for Inflammatory and Locally Advanced HER-2/NEU Negative Breast Cancer |
SWOG S0800 |
CICCOP |
| A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer |
CTSU/NCIC CTG MA.32 |
CICCOP |
| A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients |
ECOG E2108 |
CICCOP |
| A Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer *Men are not eligible to participate in this clinical trial. |
RTOG 1005 |
RTOG |
| A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer |
CTSU/CALGB 70604 |
CICCOP |
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node- Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
*Men are not eligible to participate in this clinical trial. |
NSABP B-47 |
CICCOP |
Phase II Placebo-controlled Trial of Lisinopril and Coreg CR® to Reduce Cardiotoxicity in Patients With Breast Cancer Receiving (Neo)Adjuvant Chemotherapy With Trastuzumab (Herceptin®)
*Men are not eligible to participate in this clinical trial. |
CTSU-SCUSF 0806 |
CICCOP |
Oral Curcumin for Radiation Dermatitis in Breast Cancer Patients
*Men are not eligible to participate in this clinical trial. |
URCC 10054 |
CICCOP |
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less
*Men are not eligible to participate in this clinical trial. |
SWOG S1007 |
CICCOP |
| Phase II Randomized Trial of the Combination of ABT-888 With Metronomic Oral Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low Grade Non-Hodgkin’s Lymphoma |
SCI 11-022 |
SCI |
Physical Activity Benefits after Breast Cancer: Exploring Cytokine Mechanisms
*Men are not eligible to participate in this clinical trial. |
ABLE |
SIU IM |
Enhancing Physical Activity Adherence After Breast Cancer Diagnosis: Randomized Trial
*Men are not eligible to participate in this clinical trial. |
BEAT II |
SIU IM |
A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer
*Men are not eligible to participate in this clinical trial. |
09-056 |
SCI |
Randomized Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Patients With HER2 Positive Breast Cancer Previously Treated With Trastuzumab and an Anthracycline and/or a Taxane
|
CTSU NCCTG-0733 |
CICCOP |
A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root in Breast Cancer
*Men are not eligible to participate in this clinical trial. |
07-153 |
SCI |
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
*Men are not eligible to participate in this clinical trial. |
NSABP B-43 |
CICCOP |
A Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
*Men are not eligible to participate in this clinical trial. |
SWOG S0230 |
CICCOP |
A Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer
|
SWOG S0221 |
CICCOP |
| A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen |
ECOG E3108 |
CICCOP |
| A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer *Men are not eligible to participate in this clinical trial. |
RTOG 0413 |
RTOG |
| Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer |
NSABP MA.32F |
CICCOP |
A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment
*Men are not eligible to participate in this clinical trial. |
SWOG S0500 |
CICCOP |
| Bone Pain |
|
|
A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound (Nab)-Paclitaxel or Ixabepilone Combined With Bevacizumab as First or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
*Men and women are eligible to participate in this clinical trial. |
CTSU/ CALGB 40502 |
CICCOP |
A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women With Hormone Receptor-Positive Advanced Breast Cancer
*Men are not eligible to participate in this clinical trial. |
CTSU/ CALGB 40503 |
CICCOP |
